IMforte ( ATEZOLIZUMAB PLUS LURBINECTEDIN ) : The Incidence Of Treatment-Related Adverse Events ( TRAEs ) Was 83.5% , Compared With 40% In The Control Group . Adverse Events Were Primarily Attributable To LURBINECTEDIN , Whereas ATEZOLIZUMAB Administered As Monotherapy Demonstrated a Comparatively Lower Toxicity Profile .

 

IMFORTE ( ATEZOLIZUMAB  / LURBINECTEDIN )  : LA TASA DE EVENTOS ADVERSOS RELACIONADOS CON EL TRATAMIENTO, ALCANZA EL 83,5 %, EN COMPARACIÓN CON EL 40 % EN EL GRUPO CONTROL .

 ADVERSE EVENTS  QUE APORTA LURBINECTEDIN VERSUS LOS EFECTOS ADVERSOS QUE APORTA ATEZOLIZUMAB EN MONOTERAPIA  .